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The possibility of promoting successful and active aging 
has increasingly been investigated in recent years. There is 
growing awareness that acting on the preliminary phase of the 
disabling cascade may differentiate the “successful” from the 
“pathological” aging of the individual (1). This has concurred 
at raising the interest around the so-called “frailty syndrome”. 
Frailty is a multidimensional syndrome characterized by 
reduced homeostatic reserves and increased vulnerability to 
endogenous and exogenous stressors (2). It has been associated 
with increased risk of major adverse health-related events in 
older persons (including falls, disability, hospitalization, and 
mortality) (3). At the same time, it has been indicated as a 
promising pre-disability condition to be targeted by tailored 
interventions for preventing or delaying the onset of negative 
age-related outcomes (4).
To date, frailty has been differently operationalized. Most 
of available definitions seem to have privileged the physical 
dimension of the frailty syndrome (5, 6). Nevertheless, more 
recently, the contribution of cognition to the frailty status of 
the individual has been increasingly recognized (7). A relevant 
body of literature is thus focused on the relationship between 
frailty and cognitive functioning (8, 9). Cross-sectional studies 
have repeatedly reported higher rates of cognitive impairment 
and lower cognitive performance in frail compared to robust 
elders (8). Moreover, frailty has been shown to increase the 
risk of future cognitive decline and incident dementia in 
longitudinal studies (8). Accordingly, various measures of 
cognitive performance have been included in recently proposed 
operational definitions of frailty (10).
Such emerging evidence on the topic has prompted an 
international panel of experts at recently hypothesizing and 
proposing the concept of the so-called “cognitive frailty” 
(11). This novel construct was proposed to describe a clinical 
condition characterized by the simultaneous occurrence of both 
physical frailty and cognitive impairment, in absence of overt 
dementia diagnosis or underlying neurological conditions. 
In other words, it represents the negative manifestation that 
physical frailty produces on cognition in the entropic system of 
the organism. Such hypothesis does not exclude that cognitive 
frailty may simply constitute the early sign of an incipient 
neurodegeneration responsible for future dementia. The 
underlying rationale for such novel categorization is that the 
cognitive impairment due to a physical condition would benefit 
from completely different interventions from the one caused by 
a neurodegenerative disorder. 
The concept of cognitive frailty has several elements of 
novelty. First, it fills a gap in the field by indicating (for the 
first time) a clinical entity combining both the physical and 
cognitive domains, thus more globally reflecting the health 
trajectories of the aging individual. Moreover, the detection of 
a cognitive impairment associated with a physical condition 
delineates a promising target for preventive and therapeutic 
actions. In particular, it may potentially mean improving the 
personalization of care and facilitating the design of more 
effective interventions against age-related conditions, including 
neurodegenerative disorders themselves. In fact, by better 
observing the potential causes of the cognitive impairment, it 
might be possible to improve the identification and targeting 
of patients with a “real” neurodegenerative pathogenesis and 
potentially increase the effect size of the available treatments. 
It is also noteworthy that reinforcing cognitive abilities may 
produce relevant benefits on the overall frailty status of the 
individual and reduce the risk of physical disability. Along 
the same lines, acting on physical frailty may positively affect 
cognitive functioning, thus potentially contrasting the evolution 
towards overt dementing conditions. 
Since the first publication in September 2013, the concept 
of cognitive frailty has been presented at scientific meetings 
and discussed in literature (9 articles citing the original paper 
over the last 13 months). Such interactions have stemmed 
debates in the scientific community, and allowed to identify 
specific points to be addressed and clarified. In particular, 
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potential issues negatively impacting a potential clinical and 
research implementation of the cognitive frailty construct 
have been found in a) how to operationalize its definition; b) 
the supporting epidemiological data; and c) the underlying 
clinical and biological characteristics. These aspects are briefly 




Cognitive frailty was tentatively operationalized, in occasion 
of its original conception (11), as a clinical condition meeting 
the following criteria: 
1) physical frailty; 
2) mild cognitive impairment (MCI) according to the 
Clinical Dementia Rating (CDR; i.e., score equal to 0.5) (12); 
and 
3) exclusion of concurrent Alzheimer’s disease (AD) and 
other dementias. 
Such operationalization might present some issues worth to 
be noted. While the concept of physical frailty is theoretically 
well accepted, its translation into practice is still controversial 
(3). Several instruments have been developed in order 
to properly capture this syndrome and render it objectively 
measurable (2). Unfortunately, the available definitions are 
substantially different and probably unable to exhaustively 
capture the wide and heterogeneous complexity of the condition 
of interest (13). The lack of a unique instrument for measuring 
physical frailty has affected its rapid implementation in 
everyday clinical life because limits the design, standardization, 
and development of dedicated healthcare services and 
interventions. Intuitively, all these considerations can be 
directly extended to the cognitive frailty entity. 
Cognitive impairment was arbitrary operationalized 
by considering a CDR score equal to 0.5. This choice was 
motivated by the fact that this criterion has been frequently 
adopted to indicate a condition of MCI in the dementia 
continuum (14, 15). The CDR is not a mere measure of 
cognitive performance. In fact, it describes the impact of 
cognition over the physical function (12). It is true that the 
CDR scale is widely available and relatively easy to use. 
Nevertheless, it could be argued that other operational 
definitions (for example, considering measures obtained 
through extensive and more detailed neuropsychological 
evaluations) may provide a more accurate assessment of a 
cognitive impairment of mild entity. 
Finally, the identification of a non-neurodegenerative 
cognitive impairment (i.e., cognitive frailty) inevitably implies 
the execution of diagnostic procedures (e.g., morphological 
neuroimaging) to rule out within an acceptable degree of 
approximation the existence of underlying neurological 
conditions. These instrumental assessments are expensive and 
time-consuming, thus potentially complicating the process 
required for the detection of cognitive frailty. Moreover, it 
is quite unlikely to find completely “normal” neuroimaging 
results with increasing age. In other words, at advanced 
age, it might be relatively easy to justify some cognitive 
issues with incidental neuroimaging abnormalities (e.g., 
leukoaraiosis or white matter hyperintensities), even if of 
modest amount or doubtful clinical relevance. The possible 
over-explanation of cognitive impairment in the absence of 
clear neuroimaging results may further represent an issue 
negatively affecting (i.e., underestimating) the relevance and 
prevalence of cognitive frailty in the population. Along the 
same line, the boundaries between pure neurodegenerative and 
non-neurodegenerative conditions become more vague with 
advancing age. In fact, in most of cases, neurodegenerative 
(e.g., brain atrophy) and non-neurodegenerative (e.g., vascular 
lesions) abnormalities are concomitantly detected, resulting in 
the so-called “mixed” diagnoses. This common overlap may 
limit the possibility of actually identifying cognitive frailty (i.e., 
a non-neurodegenerative cognitive impairment) in the elderly 
population. 
In order to increase the possibility of detecting cognitive 
frailty and better capturing its complex nature, a temporal 
criterion might be considered in its operational definition. That 
is, the occurrence of physical frailty should temporally precede 
the onset of cognitive impairment. This additional criterion 
(i.e., the temporal sequence of onset of frailty and cognitive 
impairment) might potentially help in the differentiation 
between a physically driven cognitive decline versus a 
cognitive deterioration independent of physical conditions.       
                            
Epidemiological data
To date, no epidemiological data about cognitive frailty has 
yet been produced. In particular, the prevalence of cognitive 
frailty is still not estimated. The few available data have been 
derived by studies enrolling highly selected populations, thus 
not representative of the general population. To our knowledge, 
only one study has indirectly provided an estimate of the 
prevalence of cognitive frailty. Shimada and colleagues, despite 
not directly talking about a “cognitive frailty” condition, 
investigated the prevalence of physical frailty and MCI in a 
sample of 5,104 Japanese older adults living in the community 
(16). The combined prevalence of frailty (defined according to 
the frailty phenotype (5)) and MCI was 2.7%. The availability 
of more consistent and specific epidemiological data will 
inevitably represent a needed step for future research and a 
possible clinical implementation of the condition of interest. 
Clinical and biological characteristics
The clinical manifestation of cognitive frailty should also 
be better described. Besides exploring the relationship between 
physical frailty and general cognitive functioning (mostly 
assessed by measures of global cognitive performance such as 
the Mini Mental State Examination (17)), a growing body of 
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literature has investigated the involvement of specific cognitive 
domains in the context of the frailty syndrome (8). To date, 
these studies have produced conflicting evidence showing that 
frailty is associated with the involvement of various cognitive 
functions such as memory, processing speed, orientation, and 
verbal fluency (8). Nevertheless, most of the available studies 
have observed a stronger and closer association with impaired 
attention and executive functioning (8, 18). Thus, it might be 
argued that a preeminent decline in executive functions might 
represent a useful element to tentatively operate a clinical 
distinction between the cognitive impairment due to physical 
versus neurological conditions. In fact, the most common 
neurodegenerative conditions (in particular, AD) are mostly 
characterized by preferential memory impairment.
These considerations may also be extended to the biological 
characteristics of cognitive frailty. Frailty and cognitive 
impairment may potentially be sustained by converging 
pathophysiological pathways (e.g., chronic inflammation, 
hormonal pathways, vascular disease, nutritional factors) (8). 
Nevertheless, there is still a lack of experimental evidence 
to support such observations. Moreover, the underlying 
mechanisms may not only be exclusively involved in the 
generation of the frailty condition, but 1) represent the main 
mechanisms regulating the organism’s homeostasis and 2) 
being largely affected by aging. In other words, it is likely that 
the foundations of frailty (as well as of cognitive frailty) are to 
be drawn in the scenario of the system biology.
  
Conclusions and future directions
The concept of cognitive frailty has been proposed for 
framing the growing and consistent evidence linking physical 
and cognitive decline in older persons within recognizable and 
discriminative standards. The clarification and implementation 
of this novel entity may provide useful insights for improving 
the discrimination of different risk profiles and provide more 
personalized preventive and/or therapeutic options. However, 
some issues still limit the clinical and research adoption of 
this concept. In particular, formulating a robust operational 
definition, providing epidemiological data (preferentially 
coming from the “real world”), and characterizing its founding 
clinical and biological basis appear to be key steps for the 
future consideration of this newborn construct.
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